These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 217022)

  • 21. Cytomegalovirus vaccines: current status.
    Starr SE
    Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination against human cytomegalovirus with live virus.
    Plotkin SA; Friedman HM; Starr S; Fleisher G
    Dev Biol Stand; 1982; 52():373-9. PubMed ID: 6299846
    [No Abstract]   [Full Text] [Related]  

  • 23. The launching of a cytomegalovirus vaccine.
    Hanshaw JB
    Am J Dis Child; 1982 Apr; 136(4):291-2. PubMed ID: 6280489
    [No Abstract]   [Full Text] [Related]  

  • 24. Cytomegalovirus vaccine live (Pasteur Mérieux Connaught).
    Drugs R D; 1999 Nov; 2(5):310-2. PubMed ID: 10728468
    [No Abstract]   [Full Text] [Related]  

  • 25. Congenital cytomegalovirus disease. Is prevention possible?
    Phillips CF
    Prog Med Virol; 1977; 23():62-8. PubMed ID: 201966
    [No Abstract]   [Full Text] [Related]  

  • 26. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.
    Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
    Lancet; 1984 Mar; 1(8376):528-30. PubMed ID: 6142252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experiments with simultaneous immunization against cytomegalovirus infection and rubella].
    Just M; Bürgin-Wolff A; Hernandez R
    Soz Praventivmed; 1976; 21(5):201-4. PubMed ID: 186979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in vaccine development for prevention of human cytomegalovirus infection.
    Gönczöl E; Plotkin S
    Curr Top Microbiol Immunol; 1990; 154():255-74. PubMed ID: 2161323
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.
    Elek SD; Stern H
    Lancet; 1974 Jan; 1(7845):1-5. PubMed ID: 4128996
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine.
    Adler SP; Hempfling SH; Starr SE; Plotkin SA; Riddell S
    Pediatr Infect Dis J; 1998 Mar; 17(3):200-6. PubMed ID: 9535246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.
    Adler SP; Starr SE; Plotkin SA; Hempfling SH; Buis J; Manning ML; Best AM
    J Infect Dis; 1995 Jan; 171(1):26-32. PubMed ID: 7798679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
    Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
    J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytomegalovirus vaccine: timing is important.
    Griffiths PD
    Rev Med Virol; 2018 Jul; 28(4):e1986. PubMed ID: 29921027
    [No Abstract]   [Full Text] [Related]  

  • 35. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial.
    Glazer JP; Friedman HM; Grossman RA; Starr SE; Barker CF; Perloff LJ; Huang ES; Plotkin SA
    Ann Intern Med; 1979 Nov; 91(5):676-83. PubMed ID: 227299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates.
    Sachs GW; Simmons RL; Balfour HH
    Vaccine; 1984 Sep; 2(3):215-8. PubMed ID: 6099649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination of pediatric nurses with live attenuated cytomegalovirus.
    Fleisher GR; Starr SE; Friedman HM; Plotkin SA
    Am J Dis Child; 1982 Apr; 136(4):294-6. PubMed ID: 6280490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.
    Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL; Duliège AM
    J Infect Dis; 1999 Nov; 180(5):1700-3. PubMed ID: 10515836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytomegalovirus vaccine work progressing.
    Gunby P
    JAMA; 1982 Sep; 248(12):1424-5. PubMed ID: 6287051
    [No Abstract]   [Full Text] [Related]  

  • 40. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
    Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
    J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.